Skip to main content
Premium Trial:

Request an Annual Quote

CytRx Completes $8.7M Private Placement

NEW YORK, Sept. 17 (GenomeWeb News) -- Los Angeles-based CytRx today announced the completion of an $8.7 million private placement of its common stock.

 

The company, which trades its stock on the Nasdaq small cap exchange, said it sold 4.1 million shares to selected institutional investors, including current shareholders. Additionally, the company, which engages in biotechnology and drug-delivery, issued warrants for the purchase of an additional 1 million shares at an exercise price of $3.05 per share, and will register all of the privately placed shares for resale. The stock closed at $2.60 on Monday.

 

CytRx said it will use $7 million of the private-placement financing to expand its RNAi-based research and development efforts in obesity and type II diabetes, which it is conducting in collaboration with the University of Massachusetts Medical School. The company will create Araios, a fully-staffed operating subsidiary to develop an orally active drug for the treatment of the two conditions. Michael Czech, chairman of the department of molecular medicine at the University of Massachusetts, will serve as scientific advisor for the subsidiary.

The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.